Axillary Lymph Node Yield Following Axillary Dissection in Biopsy‐Proven Node‐Positive Breast Cancer: Neoadjuvant Systemic Therapy Versus Primary Surgery
ANZ Journal of Surgery · 2026-05 · 96 (5) · 1190-1196
DOI: 10.1111/ans.70655 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift ANZ Journal of Surgery, online erschienen am 01.04.2026. Verfasst von Zachary Pluim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Blacktown and Mount Druitt Hospitals, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymph Node Excision, Neoadjuvant Therapy, Lymph Nodes. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neoadjuvant systemic therapy (NAST) induces morphological changes within the axilla; however, its impact on lymph node yield (LNY) following axillary lymph node dissection (ALND) is less clear.
Methods
A retrospective cohort study was performed including female patients who underwent ALND for biopsy‐proven node‐positive breast cancer within Western Sydney Local Health District hospitals between 2010 and 2022. Patients were grouped by receipt of NAST versus primary surgery (PS). LNY was compared between groups. Within the NAST group, univariate and multivariable logistic regression analyses identified variables associated with LNY ≥ 10.
Results
Among 768 patients, 217 (28.3%) received NAST and 551 (71.7%) underwent PS. Median LNY was lower following NAST compared to PS (17 [IQR: 10] vs. 21 [IQR: 10], p < 0.001), with fewer NAST patients achieving a LNY ≥ 10 compared to PS (90.8% vs. 97.5%, p < 0.001). On multivariable analysis, lymphovascular invasion (LVI) was associated with reduced odds of achieving a LNY ≥ 10 (OR: 0.26, 95% CI: 0.09–0.80, p = 0.019), whereas the HR+/HER2− subtype was associated with increased odds (OR: 3.89, 95% CI: 1.20–12.7, p = 0.024). Neither complete pathological response nor treatment effect was associated with reduced LNY.
Conclusion
NAST was associated with a modest but statistically significantly lower LNY, although median yields exceeded traditional thresholds and lymph node ratio was preserved. Following NAST, LNY appears influenced by tumour biology rather than surgical adequacy. These findings reinforce the need to interpret historic numeric thresholds cautiously, with greater emphasis on residual disease and surgical intent in modern practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Blacktown and Mount Druitt Hospitals, Sydney, New South Wales, Australia.
- School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
- Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, New South Wales, Australia.
- School of Medicine, Sydney University, Sydney, New South Wales, Australia.
- School of Medicine and Psychology, The Australian National University, Canberra, Australian Capital Territory, Australia.
ORCID-Profile: Zachary Pluim
Zitieren
APA
Pluim, Z., Huynh, R., Paredes, S., Mahajan, H., & Ngui, N. (2026). Axillary Lymph Node Yield Following Axillary Dissection in Biopsy‐Proven Node‐Positive Breast Cancer: Neoadjuvant Systemic Therapy Versus Primary Surgery. ANZ Journal of Surgery, 96(5), 1190-1196. https://doi.org/10.1111/ans.70655
Vancouver
Pluim Z, Huynh R, Paredes S, Mahajan H, Ngui N. Axillary Lymph Node Yield Following Axillary Dissection in Biopsy‐Proven Node‐Positive Breast Cancer: Neoadjuvant Systemic Therapy Versus Primary Surgery. ANZ Journal of Surgery. 2026;96(5):1190-1196. doi:10.1111/ans.70655
BibTeX
@article{Pluim2026,
author = {Pluim, Zachary and Huynh, Roy and Paredes, Steven and Mahajan, Hema and Ngui, Nicholas},
title = {Axillary Lymph Node Yield Following Axillary Dissection in Biopsy‐Proven Node‐Positive Breast Cancer: Neoadjuvant Systemic Therapy Versus Primary Surgery},
journal = {ANZ Journal of Surgery},
year = {2026},
volume = {96},
number = {5},
pages = {1190--1196},
doi = {10.1111/ans.70655}
}
EUVIMED